



Clinical Research

Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study

Claudio Maurizio Pacella¹ · Gianluigi Patelli² · Gennaro Iapicca³ · Guglielmo Manenti⁴ · Tommaso Perretta⁴ · Colleen P. Ryan⁴ · Renato Esposito⁵ · Giovanni Mauri^{6,7}

Received: 30 July 2019 / Revised: 12 November 2019 / Accepted: 28 November 2019
© The Author(s), under exclusive licence to Springer Nature Limited 2019

Abstract

Purpose To investigate the effectiveness and safety of SoracteLite™—transperineal percutaneous laser ablation (TPLA) in the treatment of patients with symptomatic benign prostatic hyperplasia (BPH) at 6 and 12 months follow-up.

Methods Patients with urinary symptoms secondary to BPH underwent TPLA under local anesthesia in four centers. Under US guidance, up to four 21G applicators were inserted in the prostatic tissue. Each treatment was performed with diode laser operating at 1064 nm changing the illumination time according to prostate size. The primary end-points of this study were change in IPSS, PVR, Qmax, QoL, and prostatic volume at 6 and 12 months from SoracteLite™ TPLA treatment. Secondary end-point was the assessment of complications.

Results Analysis was performed on data 160 patients (mean age 69.8 ± 9.6 years) with at least 6 months follow and of 83 patients (mean age 67.9 ± 8.7 years) with at least 12 months follow-up. At 6 months, IPSS improved from 22.5 ± 5.1 to 7.7 ± 3.3 ($P < 0.001$), PVR from 89.5 ± 84.6 to 27.2 ± 44.5 ml ($P < 0.001$), Qmax from 8.0 ± 3.8 to 14.3 ± 3.9 ml/s ($P < 0.001$), QoL from 4.5 ± 1.1 to 1.8 ± 1.0 ($P < 0.001$), volume from 75.0 ± 32.4 to 60.3 ± 24.5 ml ($P < 0.001$). At 12 months, IPSS improved from 22.5 ± 4.5 to 7.0 ± 2.9 ($P < 0.001$), PVR from 71.7 ± 93.9 to 17.8 ± 51.0 ml ($P < 0.001$), Qmax from 8.6 ± 5.2 to 15.0 ± 4.0 ml/s ($P < 0.001$), QoL from 4.2 ± 0.6 to 1.6 ± 0.9 ($P < 0.001$), volume from 87.9 ± 31.6 to 58.8 ± 22.9 ml ($P < 0.001$). 7/160 (4.3%) grade I and 1/160 (0.6%) grade III complication occurred.

Conclusions SoracteLite™ TPLA allows significant improvement of IPSS, QoL, Qmax, PVR, and reduction of prostatic volume at 6 and 12 months.

✉ Giovanni Mauri
giovanni.mauri@ieo.it

¹ Department of Diagnostic Imaging and Interventional Radiology, Regina Apostolorum Hospital, Via San Francesco 50, 00041 Albano Laziale, Rome, Italy

² Department of Diagnostic and Interventional Radiology, ASST Bergamoest, via Paderno 21, 24068 Seriate, Italy

³ Urology Unit, Santa Rita Clinic, Via Appia, 83042 Atripalda, Avellino, Italy

⁴ Department of Diagnostic Imaging and Interventional Radiology, Tor Vergata University, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy

⁵ iGRECO Ospedali Riuniti, Piazza Quintieri 1, 87100 Cosenza, Italy

⁶ Division of Interventional Radiology, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy

⁷ Department of Oncology and Hemato-Oncology, Faculty of Medicine and Surgery University of Milan, Milan, Italy

Introduction

Bladder outlet obstruction is a common condition affecting patients at varying severity. It affects 70% of the male population between 60 and 69 years and 80% of those aged 80 years or older [1]. In this population approximately 70% of men with benign prostatic hyperplasia (BPH) exhibit coexisting lower urinary tract symptoms (LUTS) and/or erectile dysfunction (ED) [2]. The standard medical strategies for patients with LUTS/BPH is based on alpha-blockers and/or 5-alpha reductase inhibitors. However, often these treatments do not achieve the desired results and some patients later require surgical treatments [3]. In the case that surgical treatment is required, transurethral resection of the prostate (TURP) is still the most widely applied treatment option [4]. Prostatectomy might be required for patients with very a large prostate or complicating factors. These options, though, can be

associated with a non-negligible rate of side effects and complications [5].

The flourishing of minimally invasive therapies (MITs) also arises from the need to offer options personalized based on patients and pathological factors. The available armamentarium today includes thermal therapies such as conductive transurethral needle ablation of the prostate (TUNA) [6], transurethral microwave thermotherapy (TUMT) [7], mechanical therapies such as prostatic urethral lift (PUL) [8, 9], intraoperative stents [10], intraoperative injection [11–14], and many other emerging therapies such as Rezum Convective Water Vapor Energy (WAVE) ablation [15], prostatic artery embolization (PAE) [16, 17], Aquablation™ [18, 19], and histotripsy [20]. Some of the use of these therapies are in decline while others remain experimental, some of which seem to provide promising results.

Based on recommendations for innovations in surgery [21] among various therapies, SoracteLite™—transperineal laser ablation (TPLA) has been recently proposed as a potential effective treatment modality [22]. Due to the very thin caliber of the applicators used and high precision of the energy delivery, percutaneous laser ablation has been demonstrated to be a safe and effective treatment in several pathological conditions [23, 24]. Particularly, this technique appears to be promising for the application in BPH treatment because the transperineal route avoids damage to the urethral channel. This technique has been reported to be feasible in a small preliminary study [22]. To the best of our knowledge, there is no study investigating the safety and clinical results of SoracteLite™ TPLA in a large multi-centric cohort of patients. Thus, the aim of the present paper is to investigate the effectiveness and safety of SoracteLite™ TPLA in the treatment of patients with symptomatic BPH in a large series of patients as well as the evaluation of results of this treatment at 6 and 12 months follow-ups.

Materials and methods

Centers performing transperineal laser ablation for the treatment of BPH in their routine clinical practice were contacted and asked to participate in this multi-centric retrospective study. Three centers agreed to participate, and a common database was shared for data entry among centers. Institutional review board approval was obtained.

Patients were eligible for transperineal laser treatment following criteria previously established [22]. Inclusion criteria: >50 years old with International Prostate Symptoms (IPSS) ≥ 12 , maximum urinary flow rate (Q_{\max}) <15 ml, estimated prostate volume >30 ml on transrectal ultrasonographic (TRUS) images, and post-void residual urine

volume (PVR) of <400 ml. Patients with any history of urethral stricture or prostatic surgery, confirmed prostate cancer and with known neurological disorders (neurogenic bladder) were excluded from the study. The use of anticoagulants or indwelling urinary catheters for urinary retention was not a criterion for exclusion. Also, the presence of a large median lobe was not a contraindication to the treatment. All procedures were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients signed a dedicated informed consent. Before treatment, patients completed the International Prostate Symptoms Score (IPSS) and Quality of Life (QoL) questionnaire. They underwent pressure-flow urodynamics to evaluate Q_{\max} , trans abdominal ultrasound to determine post voiding residue (PVR), and transrectal ultrasound to determine the volume of the prostate.

Transperineal laser ablation technique

The patient was placed in the radiological intervention suite in lithotomy position. A three-way Foley 18-F catheter was inserted with continuous irrigation of a saline solution during and after the maneuver. The technique has been described in detail previous literature [22]. In practice it consists of positioning up to 4 applicators (one to two per lobe, depending on prostate volume and shape) consisting of a 21-gauge Chiba needle (Strylab, Rho, Milano, Italy) as introducer in whose lumen is inserted a bare optic fiber of quartz of 300- μm until it protrudes by 10 mm from the tip of the thin introducer which was done under ultrasound guidance. The needle insertion and positioning is performed using a dedicated guidance device of the biplanar probe that allows to insert regularly spaced multiple parallel needle simultaneously. The optic fibers were connected to a multi-source laser system operating at 1.064 nm (EchoLaser X4, Elesta srl, Calenzano, Italy). A support planning tool device (ESI, Echolaser Smart Interface, Elesta srl, Calenzano, Italy), can be connected to a general US scanner and used for treatment planning. In the case of volumes less than or equal to 40 ml, a single applicator per lobe can be inserted; while in the case of a prostate with a volume greater than 40 ml two applicators per lobe are used. The tip of the fiber should be placed 8–10 mm away from the outer wall of the urethra, 15 mm from the bottom of the bladder and 10 mm from the outer edge of the prostate capsule. The position of the applicators must be carefully controlled using a biplanar ultrasound probe. In the case of two applicators, these must be positioned one after the other at a mutual distance of 8–10 mm. More generally, applicators must be positioned along a path that is as parallel as possible to the longitudinal plane of the prostate. Each treatment is

performed with patient under conscious sedation by IV of midazolam (3 mg) and with local anesthesia of the superficial tissues of the perineal region and prostate anesthesia by transrectal prostatic block with lidocaine solution 2% (20 mL). Ciprofloxacin 500 mg is used as antibiotic prophylaxis. This last maneuver has not always been followed by some operators who have started using this method to treat patients with LUTS/BPH in the light of the fact that the patients tolerate the treatment well even without the local anesthesia.

Each treatment is performed at a fixed power of 3 W changing the illumination time case by case according to prostate size. Depending on the size of the prostate, one to three consecutive illuminations are performed with a "pull-back" technique (retraction of the fibers of ~10–12 mm) during the same treatment session. The treatment ends when 1800 Joules are reached for a single illumination for each single fiber (3600 Joules for two illuminations, 5400 Joules for three illuminations). So the time needed to release maximum energy dose ranged 600–1800 s (total energy 3600–21600 Joules). The number of sources and illuminations (up to three in special cases) for each lobe can vary from the standard model described above in the case of considerable volume at baseline of the prostate greater than 100 ml, marked hyperplasia of the middle lobe and/or of asymmetry of glands' lobes. At the end of treatment, based on the patient's clinical condition, Dexamethasone 4–8 mg can administered to reduce edema. After an observation period of about one hour, the patient underwent transrectal ultrasonography with the administration of an echo-amplifier contrast agent to evaluate the extent of the coagulation zone. The coagulation area can best be evaluated in its actual extension, when possible, with Magnetic Resonance Imaging. Images of two cases are shown in Figs. 1 and 2. The SoracteLite™ system is shown in Fig. 3. The patient is kept in the hospital for one or two days and the catheter, in the absence of adverse events, is removed at the end of the treatment. In particular clinical conditions, as in the case of patients with a long history of urinary retention and those who have kept urinary catheters permanently for a long time before treatment, urinary catheters could be left in place longer according to the referring urologist.

Variable analysis

The primary end-points of this study were evaluation of change in IPSS, QoL, Qmax, PVR, and prostatic volume at 6 and 12 months from SoracteLite™ TPLA treatment. Secondary end-point was evaluation of complications after SoracteLite™ TPLA. Definition of complications was consistent with the classification of surgical complications according to the modified Clavien system (CCS) [25, 26].

Analysis was performed using GraphPad Prism 5 software (Graph-Pad, La Jolla, CA, USA). Continuous variables were expressed as mean \pm SD, and categorical variables displayed as frequencies and compared using the Mann–Whitney U test, χ^2 or Fisher test, as appropriate. A *P* value $<$ 0.05 was considered statistically significant

Results

Analysis was performed on data of 160 patients (mean age 69.8 ± 9.6 years) with a follow-up of at least 6 months and of 83 patients (mean age 67.9 ± 8.7 years) with a follow-up of at least 12 months. 36/160 (22.5%) of patients were chronic catheter carriers. Mean operation time was 44.1 ± 12.9 min, mean ablation time was 23.4 ± 10.2 min, mean energy deployed was 6616.2 ± 3880.4 J, mean hospital stay was 1.8 ± 0.4 days, and mean catheterization time was 11.3 ± 11.5 days (12.6).

At 6 months, IPSS improved from 22.5 ± 5.1 to 7.7 ± 3.3 ($P < 0.001$), PVR from 89.5 ± 84.6 to 27.2 ± 44.5 ml ($P < 0.001$), Qmax from 8.0 ± 3.8 to 14.3 ± 3.9 ml/s ($P < 0.001$), QoL from 4.5 ± 1.1 to 1.8 ± 1.0 ($P < 0.001$), volume from 75.0 ± 32.4 to 60.3 ± 24.5 ml ($P < 0.001$). At 12 months, IPSS improved from 22.5 ± 4.5 to 7.0 ± 2.9 ($P < 0.001$), PVR from 71.7 ± 93.9 to 17.8 ± 51.0 ml ($P < 0.001$), Qmax from 8.6 ± 5.2 to 15.0 ± 4.0 ml/s ($P < 0.001$), QoL from 4.2 ± 0.6 to 1.6 ± 0.9 ($P < 0.001$), volume from 87.9 ± 31.6 to 58.8 ± 22.9 ml ($P < 0.001$). Results at 6 months are reported in Table 1, and results at 12 months are reported in Table 2.

After the procedure, 7/160 (4.3%) grade I complications and 1/160 (0.6%) grade III complications occurred. Particularly, three patients experienced transient hematuria, three had acute urinary retention, and one had orchitis. The three cases of acute urinary retention were treated with a bladder catheter that was left in place for 15 days. After 15 days, the bladder catheter was removed without further complications. One patient out of one hundred and sixty (0.6%) had prostatic abscess after SoracteLite™ TPLA, which was successfully drained. Six out of one hundred and sixty (3.7%) patients experienced transient dysuria, and 2/160 (1.2%) patients independently reported lost of ejaculatory function at follow-up visit, but this was not measured by questionnaire or directly asked. Dysuria and ejaculatory disorders were regarded as sequelae.

Discussion

The results of the present multi-centric study show how SoracteLite™ TPLA can achieve significant improvement of IPSS, QoL, Qmax, PVR, and also the reduction of prostatic volume at 6 and 12 months in patients with BPH. In




Fig. 1 Case of a patient with benign prostatic hyperplasia treated with transperineal laser ablation. **a** transrectal ultrasound showing an enlarged prostate of 61.6 ml. **b**, **c** axial and longitudinal view of needle and laser fiber positioning. **d** hyperechoic area due to gas

formation at the end of the procedure. **e** contrast-enhanced ultrasound showing lack of enhancement in the treated area. **f** transrectal ultrasound showing reduction of prostatic volume to 38.4 ml at 12 months from treatment.

particular, the results obtained in this study with SoracteLite™ TPLA compare favorably with the data reported in studies with a similar follow-up period both with emerging technologies such as Aquablation [27], Rezum WAVE [15, 27], and with other different lasers such as Holmium Laser Enucleation of the Prostate (HoLEP), Green Light Photoselective Vaporization of the Prostate (PVP) [28–30]

and Thulium Laser Vapo-enucleation (ThuVEP) [31] as well as results of TURP [6, 32, 33].

In the continuous attempt to provide better results for patients, and reduce the invasiveness of treatment, the technique of prostate artery embolization (PAE) [34] has been developed by interventional radiologists and is achieving great interest. In a recent comparative




Fig. 2 3 T prostate MRI of a patient with benign prostate hyperplasia treated with transperineal laser ablation. **a** T2W axial plane medium gland pre-procedural image showing bilateral benign central gland hyperplasia with stromal rich component and pseudo-cystic intra-adenomatous spots. **b** T2W axial plane medium gland post-procedural image showing bilateral central gland thermal coagulative necrosis with almost complete adenoma vaporization and urethral sparing. **c** T1W contrast-enhanced axial plane medium gland post-procedural image showing central gland contrast-enhancement defects as a huge tailored tissue damage with selective urethral sparing.




Fig. 3 Picture shows the used devices, Echolaser X4 and ESI (Echo-laser Smart Interface), for the SoracteLite treatment in the interventional suite.

Table 1 Comparison of Qmax, RPM, IPSS, QoL, and prostate volume before treatment and at 6 months from TPLA of BPH in 160 treated patients.

	Baseline	6 months	% change	p value
IPSS	22.5 ± 5.1	7.7 ± 3.3	64.6 ± 17.0	<0.001
PVR (ml)	89.5 ± 84.6	27.2 ± 44.5	74.8 ± 26.6	<0.001
Qmax (ml/s)	8.0 ± 3.8	14.3 ± 3.9	87.1 ± 72.0	<0.001
QoL	4.5 ± 1.1	1.8 ± 1.0	56.2 ± 26.4	<0.001
Volume (ml)	75.0 ± 32.4	60.3 ± 24.5	27.2 ± 14.9	<0.001

Qmax maximum urinary flow rate, PVR post void residual, IPSS International Prostate Symptom Score, QoL Quality of Life

Table 2 Comparison of Qmax, RPM, IPSS, QoL, and prostate volume before treatment and at 12 months from TPLA of BPH in 83 treated patients.

	Baseline	12 months	% change	p value
IPSS	22.2 ± 4.5	7.0 ± 2.9	68.0 ± 12.9	<0.001
PVR (ml)	71.7 ± 93.9	17.8 ± 51.0	88.2 ± 22.9	<0.001
Qmax (ml/s)	8.6 ± 5.2	15.0 ± 4.0	88.8 ± 72.6	<0.001
QoL	4.2 ± 0.6	1.6 ± 0.9	60.7 ± 23.5	<0.001
Volume (ml)	87.9 ± 31.6	58.8 ± 22.9	33.0 ± 19.4	<0.001

Qmax maximum urinary flow rate, PVR post-void residual, IPSS International Prostate Symptom Score, QoL Quality of Life

randomized controlled trial of TURP vs PAE the difference between change in mean value of IPSS, PVR, Qmax, QoL, and Prostate Volume were 78%, 89%, 179%, 80%, and

43% vs 49%, 51%, 44%, 53%, and 19%, respectively [32, 35, 36].

In this scenario, SoracteLite™ TPLA offers some theoretical advantage over other techniques. TPLA can be

performed using the smallest available applicators on the market, thus minimizing the invasiveness related to applicators insertion. Particularly, no blood transfusions were required in our series, which are often necessary after other procedures, such as TURP. Also, the transperineal route is extremely safe, and already widely used for prostate procedures, such as biopsies, also using larger devices. Notably, the transperineal route avoids damage to the urethra, which is often involved in other kinds of treatments, such as TURP, thus theoretically reducing post-treatment irritative voiding complaints due to urothelial damage and the risk of post-treatment infections. Furthermore, the extreme precision of laser, together with the very simple system of guidance, allows for a very controlled and safe energy delivery and predictable area of ablation, thus minimizing the risk of damage on surrounding structures. The constant monitoring in real time of all the phases of the treatment allows avoidance of severe damage to the adjacent structures. Due to the particular technique, and the possibility of using multiple applicators and perform multiple ablations, it is possible also to treat effectively large prostates with initial volume larger than 100 ml. Finally, due to the minimal invasiveness of this treatment, can be easily performed under conscious sedation and with only local anesthesia, differently from other techniques which often require general or spinal anesthesia.

Complications have been reported at various incidences in the different techniques for minimally invasive treatment of patients with BPH [5, 6, 15, 27, 29, 30, 33, 37–40]. In the series reported in this study, complications were infrequent (4.3%) and according to modified CCS they were mainly grade 1 and only one (0.6%) of treated cases was grade III [26]. Six out of one hundred and sixty (3.7%) patients experienced transient dysuria, and 2/160 (1.2%) patients lost ejaculatory function; these were regarded as sequelae [25, 41]. Notably, the present data includes the initial experience with a new technique, which always requires a learning curve. Thus, the already low rate of complications reported may be even lower in the future with the increase in experience of operators. Particularly, few cases of acute transitory retention have been observed in a few patients. At the beginning of the experience, very ill patients were treated, some of whom were carrying a bladder catheter for an extended period of time before treatment. Consequently, in the first patients, the bladder catheter was kept in place for 15 days after the procedure. Increased operator experience and the adoption of treating less complicated patients, determined a change in the clinical practice; nowadays, in several patients, the bladder catheter is removed immediately after the procedure. Thus, the ideal time for bladder catheter removal is still under evaluation and clinical decision is made according to referring urologist. The preservation of sexual function is a key determinant in the

surgical pathway for patients with LUTS secondary to BPH, especially in younger men. Noteworthy is that patients treated with HoLEP or TURP had a retrograde ejaculation in over 70% [5, 42] of cases and incontinence rate ~1–2% [43]. Regarding costs of the procedure, at the time of writing this article the listed price of a single laser fiber in Europe is 600€.

Some limitations of the present work should be taken into account. First of all, this is the retrospective analysis, and no comparison with patients treated with other techniques has been performed. Prospective studies are necessary for further validate the technique, possibly comparing SoracteLite™ TPLA with other techniques such as TURP. Also, patients were treated in separate centers with a novel technique, thus results can be affected by the initial experience of the operators. Particularly, the complication rate is expected to be lowered by an increase in the experience of operators. Furthermore, only a selected subgroup of patients with at least 6 months of follow-up data available has been included in the present analysis. Studies with longer follow-up are necessary to better understand if results are sustained in the midterm and long-term period. Furthermore, ejaculatory function was not evaluated with a specific questionnaire, and thus the rate of ejaculatory complications in our series might be underestimated.

In conclusion, SoracteLite™ TPLA seems to be a safe and effective technique in the treatment of patients with BPH, demonstrating significant results sustained up to 12 months. SoracteLite™ TPLA is well tolerated by patients, does not require general anesthesia, has a low morbidity and requires short hospitalization; therefore, SoracteLite™ TPLA is rightfully taking part of the array of new techniques susceptible to wide application in patients with a long life expectancy. In order to verify the long-term durability of the results of the technique an international registry has been established by AMC-UvA (clinicaltrials.gov <https://clinicaltrials.gov/ct2/show/NCT03776006>) to recruit a large sample of patients for a broader multi-centric study.

Compliance with ethical standards

Conflict of interest GM, CMP and CR: consultant for Elesta SrL. All other authors have nothing to disclose.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. *Curr Bladder Dysfunct Rep.* 2010;5:212–8.

2. Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA, et al. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. *Urology*. 2009;73:562–6.
3. Roehrborn CG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. *Rev Urol*. 2008;10:14–25.
4. Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. *Eur Urol*. 2015;67:1066–96.
5. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. *Eur Urol*. 2006;50:969–79. discussion 980
6. Bouza C, Lopez T, Magro A, Navalpotro L, Amate JM. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. *BMC Urol*. 2006;6:14.
7. Malaeb BS, Yu X, McBean AM, Elliott SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000–2008). *Urology*. 2012;79:1111–6.
8. Perera M, Roberts MJ, Doi SA, Bolton D. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. *Eur Urol*. 2015;67:704–13.
9. Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, et al. Three year results of the prostatic urethral L.I.F. T. study. *Can J Urol*. 2015;22:7772–82.
10. Yildiz G, Bahouth Z, Halachmi S, Meyer G, Nativ O, Moskovitz B. Allium TPS—a new prostatic stent for the treatment of patients with benign prostatic obstruction: the first report. *J Endourol*. 2016;30:319–22.
11. El-Husseiny T, Buchholz N. Transurethral ethanol ablation of the prostate for symptomatic benign prostatic hyperplasia: long-term follow-up. *J Endourol*. 2011;25:477–80.
12. Shore N, Cowan B. The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. *Ther Adv Chronic Dis*. 2011;2:377–83.
13. Elhilali MM, Pommerville P, Yocum RC, Merchant R, Roehrborn CG, Denmeade SR. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. *J Urol*. 2013;189:1421–6.
14. Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. *Eur Urol*. 2013;63:496–503.
15. McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled rezum system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Urology*. 2018;111:1–9.
16. Schreuder SM, Scholtens AE, Reekers JA, Bipat S. The role of prostatic arterial embolization in patients with benign prostatic hyperplasia: a systematic review. *Cardiovasc Interventional Radiol*. 2014;37:1198–1219.
17. Pisco J, Bilhim T, Costa NV, Ribeiro MP, Fernandes L, Oliveira AG. Safety and efficacy of prostatic artery chemoembolization for prostate cancer—initial experience. *J Vasc Inter Radio*. 2018;29:298–305.
18. Yassaie O, Silverman JA, Gilling PJ. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: early results. *Curr Urol Rep*. 2017;18:91.
19. Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation - image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. *BJU Int*. 2016;117:923–9.
20. Roberts WW. Development and translation of histotripsy: current status and future directions. *Curr Opin Urol*. 2014;24:104–10.
21. McCulloch P, Cook JA, Altman DG, Heneghan C, Diener MK, Group I. IDEAL framework for surgical innovation 1: the idea and development stages. *Brit Med J*. 2013;346:f3012.
22. Patelli G, Ranieri A, Paganelli A, Mauri G, Pacella CM. Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. *Cardiovasc Interventional Radiol*. 2017;40:1440–6.
23. Pacella CM, Francica G, Di Lascio FM, Arienti V, Antico E, Caspani B, et al. Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis. *J Clin Oncol*. 2009;27:2615–21.
24. Pacella CM, Mauri G, Achille G, Barbaro D, Bizzarri G, De Feo P, et al. Outcomes and risk factors for complications of laser ablation for thyroid nodules: a multicenter study on 1531 patients. *J Clin Endocrinol Metab*. 2015;100:3903–10.
25. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg*. 2004;240:205–13.
26. Mamoulakis C, Efthimiou I, Kazoulis S, Christoulakis I, Sofras F. The modified Clavien classification system: a standardized platform for reporting complications in transurethral resection of the prostate. *World J Urol*. 2011;29:205–10.
27. Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. WATER: a double-blind, randomized, controlled trial of aquablation((R)) vs transurethral resection of the prostate in benign prostatic hyperplasia. *J Urol*. 2018;199:1252–61.
28. Krambeck AE, Handa SE, Lingeman JE. Experience with more than 1,000 holmium laser prostate enucleations for benign prostatic hyperplasia. *J Urol*. 2013;189:S141–5.
29. Tan AHH, Gilling PJ, Kennett KM, Frampton C, Westenberg AM, Fraundorfer MR. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). *J Urol*. 2003;170:1270–4.
30. Kim KS, Choi JB, Bae WJ, Kim SJ, Cho HJ, Hong SH, et al. Comparison of photoselective vaporization versus Holmium laser enucleation for treatment of benign prostate hyperplasia in a small prostate volume. *PLoS ONE*. 2016;11:e0156133.
31. Jones P, Rai BP, Somani BK, Aboumarzouk OM. A review of thulium laser vapo-enucleation of the prostate: A novel laser-based strategy for benign prostate enlargement. *Arab J Urol*. 2015;13:209–11.
32. Roberts WW. New technologies in benign prostatic hyperplasia management. *Curr Opin Urol*. 2016;26:254–8.
33. Whelan JP, Bowen JM, Burke N, Woods EA, McIssac GP, Hopkins RB, et al. A prospective trial of GreenLight PVP (HPS120) versus transurethral resection of the prostate in the treatment of lower urinary tract symptoms in Ontario, Canada. *Can Urol Assoc J*. 2013;7:335–41.
34. Yu H, Isaacson AJ, Burke CT. Review of current literature for prostatic artery embolization. *Semin Interv Radiol*. 2016;33:231–5.
35. Gao YA, Huang Y, Zhang R, Yang YD, Zhang Q, Hou M, et al. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate—a prospective, randomized, and controlled clinical trial. *Radiology*. 2014;270:920–8.
36. Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M. Transurethral resection of the prostate (TURP)

- versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective, urodynamic-controlled analysis. *Cardiovascular interventional Radiol.* 2016;39:44–52.
37. Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. *J Urol.* 2008;180:246–9.
 38. Ruszat R, Seitz M, Wyler SF, Abe C, Rieken M, Reich O, et al. GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. *Eur Urol.* 2008;54:893–901.
 39. Gillig P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-Year Results. *J Urol.* 2017;197:1565–72.
 40. Yafi FA, Tallman CT, Seard ML, Jordan ML. Aquablation outcomes for the U.S. cohort of men with LUTS due to BPH in large prostates (80–150 cc). *Int J Impot Res.* 2018;30:209–14.
 41. Rassweiler MC, Mamoulakis C, Kenngott HG, Rassweiler J, de la Rosette J, Laguna MP. Classification and detection of errors in minimally invasive surgery. *J Endourol.* 2011;25:1713–21.
 42. Montorsi F, Naspro R, Salonia A, Suardi N, Briganti A, Zanoni M, et al. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. *J Urol.* 2004;172:1926–9.
 43. Ahyai SA, Gillig P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. *Eur Urol.* 2010;58:384–97.